Infantile hemangiomas (IHs), the most common vascular tumors of infancy, are generally not present or are minimal at birth and undergo characteristic rapid growth during early infancy followed by slower growth, then gradual involution. 1 In certain locations they may impair vital functions or cause disfigurement (eg, around the eye, the nasal tip, mouth, airway). Other complications include bleeding and painful ulceration. Systemic corticosteroids, commenced in the first few weeks of life, have been the gold standard of treatment for the prevention of IH growth. They act by halting additional IH proliferation rather than inducing tumor shrinkage, and thus their usefulness is limited to the early proliferative phase. 2 Because 80% of IH growth occurs in the first 6 months, and referral for treatment is often delayed, it is frequently too late for this therapy. 3 In addition, many IHs fail to respond to steroids even in the early weeks, and therapy has significant adverse effects, including weight gain, cushingoid facies, hypertension, adrenal suppression, hyperglycemia, immunosuppression (necessitating delayed immunization), gastric irritation, behavioral changes, and transient diminished longitudinal growth. 2 Second-line therapies include vincristine and interferon-␣, which also have serious adverse effects (eg, peripheral neuropathy, spastic diplegia). 4, 5 Propranolol hydrochloride is a nonselective ␤-blocker that has been observed to produce dramatic involution of IHs in case series. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Large randomized controlled trials are under way, and many physicians are prescribing propranolol as a first-line treatment for the treatment of IHs. 17 Propranolol's exact mechanism of action is unknown. Hypotheses include decreasing arterial flow; signaling via ␤-receptors, causing endothelial cell apoptosis; and inhibition of angiogenesis. 21, 22 Known adverse effects of propranolol include hypotension, bradycardia, hypoglycemia, bronchospasm, sleep disturbance, diarrhea, and hyperkalemia. [23] [24] [25] [26] The goal of the present trial was to assess the safety and efficacy of propranolol hydrochloride for the treatment of IHs.
METHODS
A randomized, double-blind, placebo controlled, parallel-group trial was conducted in a single institution between June 2009 and December 2010. Approval was obtained from the institutional review board of the South Eastern Sydney and Illawarra Area Health Service, Northern Hospital Network Human Research Ethics Committee. Written informed consent was obtained from the children's parents after a discussion of the risks and benefits of participating.
Eligibility of Patients
Patients were recruited at a single tertiary center from pediatric dermatology, pediatric surgery, and multidisciplinary vascular anomalies clinics. Participation was offered to children between the ages of 9 weeks and 5 years with IHs that had a deep component or were located in sites that could impair function or result in aesthetic disfigurement, were too late for corticosteroid therapy, or that had failed to respond to corticosteroid therapy. Excluded were any patients with IHs requiring urgent treatment due to impingement on vital structures, patients with contraindications to propranolol, such as wheezing or PHACE (posterior fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities/aortic coarctation, and abnomalities of the eye) syndrome (the latter due to a theoretical risk of cerebral ischemia in the presence of an intracerebral vascular anomaly), and those patients with extracutaneous hemangiomas that could not be assessed by clinical photography and volume estimation. Also excluded were those patients with an inability to participate or to follow the study treatment and assessment plan.
Study Design
Patients were enrolled in the trial by study physicians and randomized into 4 groups using minimization by the clinical trials pharmacist, within the strata of age younger than 6 months (when most of the proliferation takes place), 27 age older than 6 months, and whether the hemangioma was focal or segmental. The study physician telephoned the clinical trials pharmacist who then assigned sequence of randomization. Participants, caregivers, and physicians were blinded to group status. Baseline screening comprised a cardiovascular examination, including blood pressure and heart rate, echocardiogram, electrocardiogram, full blood count, electrolytes, liver function tests, and blood glucose. The study medication was dispensed, with a ratio of 1:1, as placebo or propranolol 2 mg/kg per day and was administered according to guidelines designed in collaboration with the pediatric cardiology unit at our center. The propranolol administration and weaning regimen was developed with the advice of a pediatric cardiologist. Administration was initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24. The active drug was propranolol hydrochloride oral solution developed in Western Australia; it consisted of premade syrup with propranolol hydrochloride (British Pharmacopoeia, Norwich, United Kingdom) 10 mg per 5 mL with sodium benzoate and saccharin. The placebo oral solution had a similar taste and smell and an identical dispensing bottle.
Children younger than 6 months were initially monitored as inpatients for 4 hours with hourly measurements of blood pressure, heart rate, and blood glucose after the first dose of 1 mg/kg per day and the next week at 2 mg/kg per day. Heart rate and blood pressure measurements were compared with age-related reference ranges. A repeat electrocardiogram was obtained at week 2, and the children's blood pressure, heart rate, and blood glucose, growth and development, and any adverse events were monitored every 4 weeks for the remainder of the trial to assess safety. The dosage of propranolol or placebo was adjusted for weight at each visit, and parents were advised to feed their children around the time of medication administration. For patients with periocular IHs, ophthalmology reviews were conducted initially and as required. After 6 months of treatment, the trial medication was tapered by decreasing to onehalf dose for 1 week followed by onequarter dose for 1 week, and then discontinuing. Some children continued with open-label propranolol at the conclusion of the trial.
Outcome Measures
Response to therapy was measured by blinded volume estimation at weeks 0, 4, 8, 12, 16, 20 , and 24 by using serial hemispheric measurements of tumor volume. 28 Photographs of the IHs were taken at weeks 0, 12, and 24 by a medical photographer. The IH color (redness or blueness) and elevation were assessed by the blinded investigator and were given scores by the investigators.
Statistical Analysis
It was estimated that 20 patients per group were required to show that a 1-SD difference between groups in volume or percent change in volume would be statistically significant (P Ͻ .05; power: 80%). The data were analyzed by a statistician blinded to group coding. Volume as a primary outcome measure was discounted because, by chance, all 5 children with a large volume of 20 to 100 were in the treatment group. Percent change in volume from baseline was calculated and compared at each time point using an independent samples t test. 2 tests were used to compare redness, blueness, and elevation between groups.
RESULTS
Of 82 potential participants, 40 met the inclusion criteria and were randomly assigned to a study group, with 19 in the propranolol group and 20 in the placebo group. Figure 1 shows the number of participants involved in the trial from the assessment for eligibility through follow-up. In the placebo group, 2 patients discontinued treatment at week 4 and 1 at week 12 because of lack of efficacy. The baseline demographic and clinical characteristics of the participants in the 2 groups were similar (Table 1 ). There were 27 girls and 12 boys in the study, ranging in age from 11 weeks to 4 years. Ten children had previously been treated with systemic corticosteroids (4 in the propranolol group and 6 in the placebo (Table 4 ).
Adverse events (Table 5) included bronchiolitis, upper respiratory tract infection, and sleep disturbance with crying episodes (possibly due to nightmares). Although blood pressure, heart rate, and blood glucose were carefully measured, there were no episodes of hypotension, bradycardia, or hypoglycemia.
DISCUSSION Efficacy
Previous case series and observational studies have described the rapid onset of propranolol, with IH color changing from red to purple within 24 hours, and softening of the lesions. 
FIGURE 2
Mean percent change in volume. Most IHs halt growing between 48 hours and 1 month. [6] [7] [8] 17, 20 Our results are consistent with these findings. In the treatment group, IH involution (assessed according to percent volume change and color change) occurred early-within 4 weeks-and continued until 8 weeks (Fig 2) . The IHs became softer and less tense. For the remainder of the study, the effect seemed to plateau, with more gradual involution.
Examining serial photography, we found significant improvement in the IH redness and elevation but less change in blueness. Because all infants recruited were older than 11 weeks, only 8 infants receiving propranolol and 7 infants receiving placebo had a blueness score at week 0 compared with the larger numbers with redness and elevation scores. Blueness is quite evident during IH proliferation because the subcutaneous component of the vascular tumor appears more bluish than red beneath the skin. During IH involution, the vascular tumor is replaced by fibrofatty tissue that appears skin-colored, which could explain why this score did not show a significant improvement in our older patient population.
The dramatic response of IHs to propranolol is encouraging and suggests that early treatment of IHs could result in decreased scarring and disfigurement. With the large range of ages recruited in the trial, we included a combination of growing, plateaued, and involuting lesions. A larger response may have been seen if all children were recruited during the IH proliferation phase. It may have been difficult to discern partial responders to propranolol from natural IH involution. Additional study including larger numbers of younger and older patients would shed more light on the magnitude of the benefit of propranolol at various stages of the IH "life cycle."
Despite a lack of age uniformity in the study, percent changes in volume were shown in all children receiving propranolol, indicating effectiveness at all stages of the natural history of the tu-
FIGURE 3
Six-month-old girl with deep periocular IH responding to propranolol at weeks 0 (A), 12 (B), and 24 (C).
FIGURE 4
Four-month-old boy with a nasal tip IH treated with propranolol at weeks 0 (A), 12 (B), and 24 (C).
FIGURE 5
Twelve-month-old girl with a nasal tip IH involution with propranolol at weeks 0 (A), 12 (B), and 24 (C). mor. The medication may be particularly useful in this group to hasten involution as a replacement to early surgery or to lower the age at which timely surgery can be performed to maximize excision with minimal scarring. 29 The effectiveness of systemic corticosteroids, in contrast, is limited to the early proliferative phase.
Propranolol was not completely effective in our study, which differs from other prospective studies in which the efficacy was reported to reach 100%. 6 Other case series have classified children treated with propranolol to be excellent responders (17.2%-100%), partial responders (47%-60.4%), or nonresponders (1.7%-3%). 8, 12, [18] [19] [20] Of the 19 children receiving propranolol, a 5.5-month-old child with a periocular IH had a measurable but small response to propranolol with initial volume reduction but persistent erythema and elevation (Fig 6) . Another child (11 months of age) with a large focal IH on her back experienced ulceration that took 2 months to heal, with partial IH involution during the trial. It is unclear why some IHs do not respond as well as others, and whether this is related to factors such as tumor blood supply or expression of ␤-adrenergic receptors.
Adverse Effects
The most common serious adverse effects of propranolol are bradycardia and hypotension. 23, 25 Other reported adverse effects include bronchospasm, congestive heart failure, hypoglycemia, hypothermia, somnolence, sleep disturbance, nightmares, depression, nausea, vomiting, diarrhea, hyperkalemia, gastroesophageal reflux, psoriatic drug rash, and respiratory syncytial virus exacerbation. 7, 12, 24, 25 Propranolol was generally well tolerated in this trial. Children remained hemodynamically stable, with 1 child experiencing transient cool extremities that improved after several weeks. Four children in the propranolol group and 1 child in the placebo group developed bronchiolitis. Two children were followed and treated with inhaled fluticasone propionate during the trial, while continuing propranolol. Because of their young age, they were thought to have viralinduced reactive airways rather than asthma, and there was a family history of atopy in 1 child. Another infant taking propranolol discontinued the study after developing an upper respiratory tract infection, although there was no wheezing. Other illnesses included a hospital admission for a streptococcal infection, and a child with viral gastroenteritis. One child receiving placebo developed astigmatism and was discontinued from the trial. His astigmatism resolved within 8 weeks of being treated with open-label propranolol. Another child developed dental caries involving molars that erupted while receiving propranolol. Our propranolol suspension contained an artificial sweetener rather than sugar. Caries have been reported with propranolol, and there is some experimental evidence to indicate decreased salivation induced by propranolol. 30 Two children developed IH ulceration, and the child receiving placebo was discontinued from the study due to ulceration within a nasal tip hemangioma. The ulcer healed and nasal tip IH involuted when he was switched to open-label propranolol. The 4 children with sleep disturbances had their medication adjusted to twice daily, rather than 3 times daily (eliminating the evening dose), with improvement in symptoms for the 2 children taking propranolol. Laboratory investigations were performed as baseline investigations as a precaution because this was a clinical trial. Elevated alkaline phosphatase levels (thought to be transient hyperphosphatasemia of infancy) were observed in 1 child and resolved within 2 months. Hypoglycemia was not detected with our routine blood glucose monitoring, and children did not have symptoms, such as fussiness, to suggest hypoglycemia. Parents were advised to discontinue the study medication if the child had an intercurrent illness associated with decreased oral intake. Although hyperkalemia has been reported in a systemically unwell, premature infant treated with propranolol, 24 apart from monitoring blood glucose we would not recommend routine monitoring of electrolytes, blood counts, or liver function in otherwise healthy children. For clinicians prescribing propranolol, we suggest following a written protocol and counseling parents regarding potential medication adverse effects.
Although rebound growth was not formally assessed as part of the study, a mild rebound growth of IHs (with increased redness or slight increase in
FIGURE 6
Five-month-old girl with minimal response of IH on left eyebrow to propranolol at weeks 0 (A), 12 (B), and 24 (C).
volume) was noted on cessation of propranolol. Rebound was more noticeable in the children younger than 1 year. Although most IH growth occurs in the first 9 weeks, IHs with a significant subcutaneous component may continue to proliferate up to a year, suggesting that treatment may be required throughout the proliferative phase up to 1 year. Segmental IHs have been reported to continue to proliferate for even longer, to a mean age of 17 months. 31 On the basis of our findings, we would suggest a treatment course of at least 6 months, which could be adjusted according to the IH subtype. The optimal duration of treatment and optimal dosage regimen remains to be established in future studies. Dose ranges of 1 to 3 mg/kg per day have been evaluated in case series and are given either 2 or 3 times daily. 19, 20 An advantage of twice-daily dosing would be ease of medication administration and perhaps decreased risk of nocturnal hypoglycemia. The dosage of 2 mg/kg per day was well tolerated by our patients, and the study was designed with 3 divided dosages because of concerns regarding the short halflife of propranolol (3-6 hours). 32
Limitations
Study limitations were our heterogeneous patient population and small numbers. Most children were older than 6 months, and their hemangiomas were of different sizes. Measurement error was a potential limitation of our volume measurements, and for smaller hemangiomas, a small change in the hemispheric measurement made a significant change in volume compared with the larger hemangiomas. In addition, the study did not set out to assess the duration of treatment required to maintain regression in the 2 groups, a question that should be the subject of additional study.
CONCLUSIONS
This randomized controlled trial revealed that propranolol is a safe and effective medication for treating IHs. Even with small numbers and a heterogeneous group, the P values show significant volume reduction and redness/elevation reduction sufficient to justify the use of propranolol as the first-line option for potentially disfiguring or complicated IHs. Larger multicenter trials may confirm these results and provide more detailed information regarding the use in different age groups and anatomic sites, and the safety of propranolol in this patient population.
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